Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients

Tetsuya Yasunaka, Fusao Ikeda, Nozomu Wada, Yuki Morimoto, Shin ichi Fujioka, Junichi Toshimori, Haruhiko Kobashi, Kazuya Kariyama, Yoichi Morimoto, Hiroki Takayama, Tomonori Seno, Koichi Takaguchi, Akio Moriya, Hirokazu Miyatake, Ryoichi Okamoto, Kazuhisa Yabushita, Akinobu Takaki, Kazuhide Yamamoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged ≥ 35 years, HBV DNA ≥ 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged ≥ 35 years with HBV DNA ≥ 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged 35 years with HBV DNA ≥ 4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalActa medica Okayama
Volume70
Issue number1
Publication statusPublished - 2016

Keywords

  • Entecavir
  • Hepatitis B virus
  • Hepatocellular carcinoma
  • Lamivudine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients'. Together they form a unique fingerprint.

  • Cite this

    Yasunaka, T., Ikeda, F., Wada, N., Morimoto, Y., Fujioka, S. I., Toshimori, J., Kobashi, H., Kariyama, K., Morimoto, Y., Takayama, H., Seno, T., Takaguchi, K., Moriya, A., Miyatake, H., Okamoto, R., Yabushita, K., Takaki, A., & Yamamoto, K. (2016). Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients. Acta medica Okayama, 70(1), 1-12.